Filtered By:
Condition: Heart Failure
Nutrition: Vitamins

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 268 results found since Jan 2013.

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF Arrhythmia and Electrophysiology
Conclusions In a large population of patients anticoagulated for nonvalvular atrial fibrillation, 7 in 10 deaths were cardiovascular, whereas <1 in 10 deaths were caused by nonhemorrhagic stroke or systemic embolism. Optimal prevention and treatment of heart failure, renal impairment, chronic obstructive pulmonary disease, and diabetes may improve survival. Clinical Trial Registration URL: https://www.clinicaltrials.gov/. Unique identifier: NCT00403767.
Source: JAHA:Journal of the American Heart Association - March 7, 2016 Category: Cardiology Authors: Pokorney, S. D., Piccini, J. P., Stevens, S. R., Patel, M. R., Pieper, K. S., Halperin, J. L., Breithardt, G., Singer, D. E., Hankey, G. J., Hacke, W., Becker, R. C., Berkowitz, S. D., Nessel, C. C., Mahaffey, K. W., Fox, K. A. A., Califf, R. M., for the Tags: Atrial Fibrillation, Sudden Cardiac Death, Heart Failure, Intracranial Hemorrhage, Ischemic Stroke Arrhythmia and Electrophysiology Source Type: research

What do the guidelines suggest for non-vitamin K antagonist oral anticoagulant use for stroke prevention in atrial fibrillation?
This article provides an overview of the current international guidelines with regard to NOAC use and highlights key areas by which emerging evidence may change the management of stroke prevention in patients with non-valvular AF.
Source: European Journal of Heart Failure Supplements - December 21, 2016 Category: Cardiology Authors: Shahid, F., Shantsila, E., Lip, G. Y. H. Tags: Articles Source Type: research

Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF
ConclusionGARFIELD-AF data highlights marked heterogeneity in stroke prevention strategies globally. Physicians are adopting an individualized approach to stroke prevention where NOACs are favored in patients with a lower stroke risk, but also in the elderly and patients with ACS.
Source: American Heart Journal - April 11, 2019 Category: Cardiology Source Type: research

Combination of Oral Anticoagulants and Single Antiplatelets versus Triple Therapy in Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome: Stroke Prevention among Asians
Int J Angiol DOI: 10.1055/s-0040-1708477Atrial fibrillation (AF), the most prevalent arrhythmic disease, tends to foster thrombus formation due to hemodynamic disturbances, leading to severe disabling and even fatal thromboembolic diseases. Meanwhile, patients with AF may also present with acute coronary syndrome (ACS) and coronary artery disease (CAD) requiring stenting, which creates a clinical dilemma considering that majority of such patients will likely receive oral anticoagulants (OACs) for stroke prevention and require additional double antiplatelet treatment (DAPT) to reduce recurrent cardiac events and in-stent th...
Source: International Journal of Angiology - May 5, 2020 Category: Cardiology Authors: Santoso, Anwar Raharjo, Sunu B. Tags: Invited Papers Source Type: research

Stroke Prevention in Atrial Fibrillation in Heart Failure
Heart failure and atrial fibrillation are major problems of modern cardiology with important clinical, prognostic, and socioeconomic implications. The risks are high morbidity, impaired quality of life, poor outcome, and increased risk of stroke. Oral anticoagulation with vitamin K antagonists or novel licensed medicines should be considered unless contraindicated. Possible benefits of sinus rhythm maintenance are not entirely clear and need to be explored further. Relatively scarce data are available on stroke prevention in atrial fibrillation in heart failure with preserved ejection fraction; this requires further research.
Source: Heart Failure Clinics - September 23, 2013 Category: Cardiology Authors: Eduard Shantsila, Gregory Y.H. Lip Source Type: research

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Publication date: Available online 6 March 2015 Source:The Lancet Author(s): Jeffrey B Washam , Susanna R Stevens , Yuliya Lokhnygina , Jonathan L Halperin , Günter Breithardt , Daniel E Singer , Kenneth W Mahaffey , Graeme J Hankey , Scott D Berkowitz , Christopher C Nessel , Keith A A Fox , Robert M Califf , Jonathan P Piccini , Manesh R Patel Background Digoxin is a widely used drug for ventricular rate control in patients with atrial fibrillation (AF), despite a scarcity of randomised trial data. We studied the use and outcomes of digoxin in patients in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Com...
Source: The Lancet - March 6, 2015 Category: Journals (General) Source Type: research

Left atrial appendage closure for stroke prevention in nonvalvular atrial fibrillation: A current overview
J Cardiol. 2022 Nov 15:S0914-5087(22)00277-5. doi: 10.1016/j.jjcc.2022.11.006. Online ahead of print.ABSTRACTAtrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice and its prevalence increases with age. AF causes palpitations, heart failure, and cardiogenic embolism. Of them, the most critical and fatal complication is a cardio-embolic event. Oral anticoagulation plays a central role in reducing stroke risk in AF patients. Recently, when oral anticoagulation is considered in patients with non-valvular AF who are eligible for direct oral coagulations, they are preferred to vitamin K antagoni...
Source: Journal of Cardiology - November 18, 2022 Category: Cardiology Authors: Hiroshi Ueno Teruhiko Imamura Shuhei Tanaka Nobuyuki Fukuda Koichiro Kinugawa Source Type: research

Recurrent stroke and myocardial infarction in a young woman with severe osteoporosis and hyperparathyroidism
We have taken great interest in the recently published article entitled “ Effect of calcium or vitamin D supplementation on vascular outcomes: A meta-analysis of randomized controlled trial” . Likewise, since parathormone (PTH) is a vasoactive peptide, we, herein, wish to draw attention to the fact that primary hyperparathyroidism (pHPT) can –as well– be in association with increased risk of cardiovascular diseases (i.e. myocardial infarction (MI), heart failure, thrombosis or cardioembolism, hypertension), stroke and osteoporosis . In this regard, we exemplify the clinical scenario of one of our pertinent patients.
Source: International Journal of Cardiology - January 21, 2014 Category: Cardiology Authors: Murat Kara, Levent Özçakar, Hatice Gözde Sümer, Timur Ekiz, Sibel Özbudak Demir, Ayşen Akıncı Tags: Online Letters to the Editor Source Type: research

Stroke risk reduction with oral anticoagulation using CHADS-VASc in a Japanese AF population: a modeling analysis
Current clinical guidelines recommend that risk stratification for ischaemic stroke in patients with nonvalvular AF (NVAF) should be performed using the CHA2DS2-VASc score (Congestive heart failure, Hypertension, Age≥75years [double], Diabetes mellitus, previous thromboembolism [double], Vascular disease, Age 65–74 years, and female gender) to aid decision making for antithrombotic treatment, with a preference for Non-Vitamin K Oral Anticoagulants (NOACs) in those with CHA2DS2-VASc score ≥1. However, CHA2DS2-VASc score is not recommended in the 2014 Japanese Circulation Society (JCS) guidelines for patients with NVAF.
Source: International Journal of Cardiology - December 5, 2014 Category: Cardiology Authors: Keitaro Senoo, Deirdre A. Lane, Gregory Y.H. Lip Source Type: research

Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation
Expert Opin Investig Drugs. 2021 Mar 8. doi: 10.1080/13543784.2021.1897786. Online ahead of print.ABSTRACTINTRODUCTION: Atrial fibrillation is the most frequently diagnosed cardiac arrhythmia globally and is associated with ischemic stroke and heart failure. Patients with atrial fibrillation are typically prescribed long term anticoagulants in the form of either vitamin K antagonists or non-vitamin K antagonist oral anticoagulants; however, both carry a potential risk of adverse bleeding.AREAS COVERED: This paper sheds light on emerging anticoagulant agents which target clotting factors XI and XII, or their activated forms...
Source: Expert Opinion on Investigational Drugs - March 8, 2021 Category: Drugs & Pharmacology Authors: Robert Bentley Lewis J Hardy Laura J Scott Parveen Sharma Helen Philippou Gregory Y H Lip Source Type: research

Percutaneous Left Atrial Appendage Suture Ligation Not Ready for Prime Time ∗
Novel approaches to reduce stroke risk with oral anticoagulant medications or interventions are of the utmost importance to improve the quality of care for patients with atrial fibrillation (AF). Oral anticoagulation with vitamin K antagonists and, more recently, with novel oral anticoagulants (NOACs) has led to a remarkable reduction of stroke risk; however, some of the benefits with NOACs are counterbalanced by increased bleeding risks. The idea of developing interventions that reduce stroke risk but avoid long-term oral anticoagulation and thereby avoid increasing the bleeding risk appears very reasonable and attractive...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - August 4, 2014 Category: Cardiology Source Type: research